度洛西汀联合乙哌立松对紧张性头痛伴焦虑障碍患者的疗效观察

Effect of duloxetine combined with eperisone for tension headache patients with anxiety disorder

  • 摘要:
      目的  探讨度洛西汀联合乙哌立松对紧张性头痛伴焦虑障碍患者的疗效。
      方法  选取在门诊治疗的50例紧张性头痛伴焦虑障碍患者作为研究对象,将其随机分为实验组与对照组,各25例。实验组患者采用盐酸乙哌立松片联合盐酸度洛西汀肠溶胶囊治疗,对照组仅采用盐酸乙哌立松片治疗。所有患者观察4周,实验过程中采用副反应量表(TESS)评定副反应,实验开始及结束时采用视觉模拟评分法(VAS)判断患者头痛程度,并采用汉密尔顿焦虑量表(HAMA)评估焦虑程度。
      结果  治疗后, 2组患者的VAS评分均较治疗前显著下降(P < 0.05), 且实验组VAS评分显著低于对照组(P < 0.05);治疗后, 2组患者的HAMA评分均较治疗前显著下降(P < 0.05), 且实验组HAMA评分显著低于对照组(P < 0.05); 2组的副反应发生率比较,差异无统计学意义(P>0.05)。
      结论  度洛西汀联合乙哌立松可有效且安全地缓解紧张性头痛伴焦虑障碍患者的症状。

     

    Abstract:
      Objective  To investigate the efficacy of duloxetine combined with eperisone in tension headache patients with anxiety disorder.
      Methods  Fifty tension headache patients with anxiety disorder who were treated in outpatient clinic were selected as subjects, and were randomly divided into experimental group and control group, with 25 cases in each group. The patients in the experimental group were treated with eperisone hydrochloride tablets combined with duloxetine enteric-coated capsules, and the control group was only treated with eperisone hydrochloride tablets. All patients were observed for 4 weeks. The side effects were assessed by the Side Effects Scale (TESS). The Visual Analogue Scale (VAS) was used to evaluate the degree of headache at the beginning and end of the study, and the anxiety was assessed using the Hamilton Anxiety Scale (HAMA).
      Results  After treatment, the VAS scores and HAMA scores of the two groups were significantly lower than treatment before (P < 0.05), and the indicators in the experimental group were significantly lower than that of the control group (P < 0.05). There was no significant difference in the incidence of side reactions between the two groups (P>0.05).
      Conclusion  Duloxetine combined with eperisone can effectively and safely relieve the symptoms of patients with tension headache and anxiety disorders.

     

/

返回文章
返回